Heparin Sodium (Heparin Sodium,Porcine) Patent Expiration, LOE Window & CMS Spending

Heparin Sodium (Heparin Sodium,Porcine) by Fresenius Kabi: Off-Patent Uncontested (0 AB Generics), 0 AB generics, $202.8M 2024 CMS Part D & Medicaid spend, and 23 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayN017029 (NDA)
Exclusivity / Cliff HorizonOff-Patent Uncontested (0 AB Generics)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$202.8M
2024 Medicare Part D Spend$2.4M
2024 Medicaid Spend$200.3M
Reported Wholesale Price Change (CA SB 17)23 WAC filings (max 347.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.